Press Releases

Press Releases

Date Title  
Mar 19, 2018
REDWOOD CITY, Calif. , March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2017 .
Mar 19, 2018
REDWOOD CITY, Calif. , March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2017 .
Mar 13, 2018
Three New Patents Allowed or Issued for Proprietary CTO Crossing Devices REDWOOD CITY, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced three recent additions to its U.S.
Mar 06, 2018
REDWOOD CITY, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2017 after the close of trading on
Mar 05, 2018
REDWOOD CITY, Calif , March 05, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will be participating in the Cowen and Company 38th Annual Health Care Conference in Boston .
Mar 02, 2018
REDWOOD CITY, Calif. , March 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced it has regained compliance with Nasdaq listing requirements.  In a letter dated March 1, 2018 , Nasdaq informed
Feb 20, 2018
New Code is a Potential Precursor to Higher Reimbursement Levels in German DRG System REDWOOD CITY, Calif. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced that the German Institute for
Feb 16, 2018
Secured Lenders Convert $38 Million of Debt into Equity REDWOOD CITY, Calif. , Feb. 16, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the closing of an underwritten public offering of Series B
Feb 14, 2018
Secured Lenders Convert $38 Million of Debt into Equity REDWOOD CITY, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten public offering of Series B
Feb 02, 2018
Leipzig Interventional Course is a leading global forum for new methods and technology in the field of vascular medicine REDWOOD CITY, Calif. , Feb. 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced